Overview

Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

Status:
RECRUITING

Trial end date:
2027-08-29

Target enrollment:

Participant gender:

Summary

This extension study is designed to enroll participants with hematologic malignancies who are receiving clinical benefit from tafasitamab treatment in a parent study with tafasitamab..

Phase:

PHASE2

Details

Lead Sponsor:

Incyte Corporation

Treatments:

tafasitamab